|
Back to EZorb Newsletter Index |
|
In this issue:
Letter I: From Norma V. Dear Folks at Elixir, Happy New Year! Just want to share with you the best news for the New Year! I had my DEXA results back Yesterday and I'm speechless. T-score for lumbar spine improved to -3.1 from -3.6 (2 years ago). T-score for my hip also improved slightly, from -2.9 to -2.8. I was so scared coz my doctor told me I could break my back at any time. He wanted me to take Alendronate, which made me so sick after just two doses. And I later found out it's only going to make my bones more brittle. I'm so glad I got on EZorb. It was a big decision but it's so worth it! Norma V. Letter II: From Paul Hi, my name is Paul. My wife (then fiance) was experiencing lots of pain in her feet every time that she walked. She went to a foot specialist who took x-rays and told her that she had heel spurs. He told her he wanted to see her again in six months and if there was no improvement, then she would be needing surgery to remove the spurs. My wife then was doing searches online to find out more about heel spurs and the removal process and during a search ending up coming across Ezorb. She read about it, then showed it to me when I got home from work. We ordered some for her to try. After the second month, she started to notice the pain was slowly going away. When she went back for her six month checkup, the Dr. took more x-rays and put them up for comparison against the previous ones. He look confused and was looking back and forth between the x-rays and the bottoms of her feet. He turned to her and asked "who did your surgery? I can't even tell that you had surgery." She smiled and told him that she didn't have any surgery, that she took a product called Ezorb and it dissolved the heel spurs. He was shocked and asked her for the name of the product again-wrote it down and said "I'm going to recommend this to a bunch of my patients!" We have been telling family/friends about Ezorb and how good it is as well as how good it works. From the Desk of EZorb Newsletter Editor:Our newsletter reaches over 200,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life. Please email your story to sharesuccess @ ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public. 2. Research News: Hip Fracture Risk During Drug Holiday: Risedronate (Actonel) vs Alendronate (Fosamax)The risk for hip fracture is higher during a treatment break from risedronate than it is during a break from alendronate, study findings indicate. Kaleen Hayes (Brown University School of Public Health, Providence, Rhode Island, USA) and colleagues explain that a drug holiday is generally recommended after 3 to 5 years of osteoporosis therapy, but the evidence for this mainly comes from the FLEX trial for alendronate. They note that the “fracture risk during drug holidays has not been directly compared between alendronate and risedronate,” even though “risedronate has an approximately 50% weaker binding affinity than alendronate and a lower saturation point in bone due to the molecule's more neutral charge,” meaning that “the residual length of fracture protection may be shorter.” To address this, Hayes et al analyzed propensity score-matched data for 50,154 individuals aged 66 years and older who received at least 3 years of continuous (80% adherence) risedronate or alendronate therapy followed by a drug holiday of at least 120 days. During 3 years of follow-up, which began after a 120-day ascertainment period, 3.3% of all participants experienced a hip fracture. The incidence rates were 12.4 events per 1000 person-years in the risedronate group and 10.6 events per 1000 person-years in the alendronate group, corresponding to a significant 18% higher risk during risedronate than alendronate drug holidays. “This relative effect reflects a low increased absolute risk (3-year risk difference of 0.6 percentage points), with a corresponding number needed to treat of 167 patients with alendronate instead of risedronate to prevent 1 hip fracture,” the researchers write in the Annals of Internal Medicine. Of note, the association was attenuated and no longer statistically significant when the drug holiday duration was shortened to 1 or 2 years but the hazard ratio increased with increasing length of follow-up. Indeed, when the analyses were limited to 2 to 3 years of follow-up, the risk for hip fracture was a significant 34% higher in the risedronate versus alendronate groups. Hayes and co-authors stress, however, that their findings “do not indicate that alendronate therapy should be preferred over risedronate therapy.” “Indeed, several real-world studies identify little difference in fractures while treatment is received,” they say. The researchers conclude: “To further inform clinical decision making on drug holidays, future research should examine when to start and restart osteoporosis therapy on the basis of initial length and type of treatment, patient characteristics, and relative risk for hip fractures versus atypical femoral fractures.” Original research was published in Ann Intern Med 2022; doi:10.7326/M21-2512. 3. Useful LinksEZorb - Frequently Asked Questions & Answers 4. What Are Others Saying About EZorb and Marvlix?EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families
around the world. Click here to read what people say about EZorb
and Marvlix. |
|
Back to EZorb Newsletter Index |